NASDAQ:SABS SAB Biotherapeutics (SABS) Stock Forecast, Price & News $0.67 +0.01 (+1.52%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$0.63▼$0.7050-Day Range$0.47▼$0.8552-Week Range$0.37▼$1.45Volume90,836 shsAverage Volume486,379 shsMarket Capitalization$35.05 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SAB Biotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside198.5% Upside$2.00 Price TargetShort InterestHealthy0.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector202nd out of 966 stocksBiological Products, Except Diagnostic Industry25th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingSAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, SAB Biotherapeutics has a forecasted upside of 198.5% from its current price of $0.67.Amount of Analyst CoverageSAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.82% of the float of SAB Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSAB Biotherapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in SAB Biotherapeutics has recently decreased by 17.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSAB Biotherapeutics does not currently pay a dividend.Dividend GrowthSAB Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SABS. Previous Next 3.4 News and Social Media Coverage News SentimentSAB Biotherapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for SABS on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.90% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.82% of the stock of SAB Biotherapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SAB Biotherapeutics are expected to grow in the coming year, from ($0.49) to ($0.38) per share.Price to Book Value per Share RatioSAB Biotherapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SAB Biotherapeutics (NASDAQ:SABS) StockSAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.Read More SABS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SABS Stock News HeadlinesOctober 3, 2023 | finance.yahoo.comSAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes TreatmentOctober 2, 2023 | finance.yahoo.comEXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes CandidateOctober 4, 2023 | Chaikin Analytics (Ad)Something is Coming for America's Top StockThis stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.October 2, 2023 | finance.yahoo.comSAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesAugust 22, 2023 | seekingalpha.comSAB Biotherapeutics GAAP EPS of -$0.14August 22, 2023 | markets.businessinsider.comSAB Biotherapeutics (SABS) Gets a Buy from Chardan CapitalAugust 21, 2023 | benzinga.comAnalyst Ratings for SAB BiotherapeuticsAugust 21, 2023 | markets.businessinsider.comSAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsOctober 4, 2023 | Chaikin Analytics (Ad)Something is Coming for America's Top StockThis stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.August 21, 2023 | markets.businessinsider.comSAB Biotherapeutics (SABS) Receives a Buy from H.C. WainwrightAugust 21, 2023 | finance.yahoo.comSAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsJuly 12, 2023 | finance.yahoo.comSwiss Franc Jumps to Highest Against Dollar Since SNB Lifted CapJune 21, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics Says Diabetes Immunotherapy Shows Therapeutic Effect In Toxicology StudyJune 21, 2023 | finance.yahoo.comSAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023June 16, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on SAB Biotherapeutics (SABS)May 30, 2023 | finance.yahoo.comSAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionMay 19, 2023 | finance.yahoo.comSAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsMay 16, 2023 | msn.comSAB Biotherapeutics: Q1 Earnings InsightsMay 16, 2023 | finanznachrichten.deSAB Biotherapeutics, Inc.: SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsMay 16, 2023 | finance.yahoo.comSAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsMay 12, 2023 | finance.yahoo.comSAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesMay 11, 2023 | barrons.comSAB Biotherapeutics Inc.May 9, 2023 | marketwatch.comSAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's Groundbreaking DiversitAb(TM) PlatformMay 4, 2023 | msn.comEXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage TrialsMay 3, 2023 | finance.yahoo.comSAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11April 29, 2023 | marketwatch.com8-K: SAB Biotherapeutics, Inc.April 26, 2023 | finance.yahoo.comSAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185See More Headlines Receive SABS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SABS Company Calendar Last Earnings8/21/2023Today10/04/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SABS CUSIPN/A CIK1833214 Webwww.bigcypressaccorp.com Phone605-679-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$2.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+198.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,740,000.00 Net Margins-454.82% Pretax Margin-454.42% Return on Equity-110.34% Return on Assets-64.31% Debt Debt-to-Equity Ratio0.20 Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$23.90 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book0.93Miscellaneous Outstanding Shares52,320,000Free Float35,629,000Market Cap$35.05 million OptionableNot Optionable Beta1.34 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Samuel J. Reich (Age 48)Exec. Chairman Comp: $376.2kDr. Eddie Joe Sullivan Ph.D. (Age 57)Co-Founder, Pres, CEO & Director Comp: $430.62kMs. Christine E. Hamilton M.B.A. (Age 67)Co-Founder & Independent Director Comp: $25kDr. Alexandra Kropotova M.B.A. (Age 50)M.D., Exec. VP & Chief Medical Officer Comp: $486.96kDr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverMr. Russell P. Beyer C.M.A. (Age 68)M.B.A., Exec. VP & CFO Dr. Christoph Bausch M.B.A. (Age 52)Ph.D., Exec. VP & COO Dr. Carlos N. Carillo Ph.D.Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsCurisNASDAQ:CRISAcorda TherapeuticsNASDAQ:ACORSangamo TherapeuticsNASDAQ:SGMOCortexymeNASDAQ:CRTXMiromatrix MedicalNASDAQ:MIROView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 54,400 shares on 8/11/2023Ownership: 0.108%BlackRock Inc.Sold 57,370 shares on 8/11/2023Ownership: 0.104%Institutional & Family Asset Management LLCBought 42,253 shares on 8/9/2023Ownership: 0.381%View All Institutional Transactions SABS Stock - Frequently Asked Questions Should I buy or sell SAB Biotherapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SABS shares. View SABS analyst ratings or view top-rated stocks. What is SAB Biotherapeutics' stock price forecast for 2023? 1 analysts have issued twelve-month price objectives for SAB Biotherapeutics' shares. Their SABS share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts. How have SABS shares performed in 2023? SAB Biotherapeutics' stock was trading at $0.5899 at the beginning of the year. Since then, SABS shares have increased by 13.6% and is now trading at $0.67. View the best growth stocks for 2023 here. Are investors shorting SAB Biotherapeutics? SAB Biotherapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 306,500 shares, a decrease of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio is presently 8.5 days. Approximately 0.8% of the shares of the company are short sold. View SAB Biotherapeutics' Short Interest. When is SAB Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our SABS earnings forecast. How were SAB Biotherapeutics' earnings last quarter? SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14). The firm earned $0.09 million during the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 110.34% and a negative net margin of 454.82%. What is SAB Biotherapeutics' stock symbol? SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS." How do I buy shares of SAB Biotherapeutics? Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SAB Biotherapeutics' stock price today? One share of SABS stock can currently be purchased for approximately $0.67. How much money does SAB Biotherapeutics make? SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $35.05 million and generates $23.90 million in revenue each year. How can I contact SAB Biotherapeutics? SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com. This page (NASDAQ:SABS) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.